Free DNA partially clarifies discrepancies between qPCR and the conventional phage quantification method

PLoS One. 2024 Dec 3;19(12):e0313774. doi: 10.1371/journal.pone.0313774. eCollection 2024.

Abstract

To use phages in a personalized therapy and industrial applications, an accurate quantification is needed. The gold standard method, namely the culture-based double agar overlay (DAO) method, provides an accurate estimate of the number of infectious phages but is laborious and time-intensive. Quantitative polymerase chain reaction (qPCR) can be used as a fast alternative but tends to overestimate the number of infectious phage particles. Here we describe the use of a DNase treatment before quantification of the Staphylococcus aureus phage ISP with qPCR to obtain a more accurate estimate of the number of infectious phage particles. We showed that DNase treatment results in a significant decrease of the concentration when measured with qPCR although for two out of three tested ISP phage stocks, there was still a significant difference with the DAO method. We also showed that the discrepancy between quantification with qPCR and the DAO method is dependent on the storage period of the phage stock, with a larger discrepancy for older stocks. Additionally, we used negative contrast immune electron microscopy to confirm the presence of DNA in the medium of the phage stock and the impact of the DNase treatment on the free DNA.

MeSH terms

  • Bacteriophages / genetics
  • DNA, Viral* / genetics
  • Deoxyribonucleases / metabolism
  • Polymerase Chain Reaction / methods
  • Real-Time Polymerase Chain Reaction / methods
  • Staphylococcus Phages / genetics
  • Staphylococcus aureus* / genetics
  • Staphylococcus aureus* / virology

Substances

  • DNA, Viral
  • Deoxyribonucleases

Grants and funding

This work has been supported by the Ghent University Hospital, The Flemish government and the University College Ghent by funding of the PWO project “Quantitative phage control for safe treatment of bacterial invasive species in cystic fibrosis patients” (MucoPhage) and Fund Alphonse and Jean Forton, managed by the King Baudouin Foundation and the Belgian Cystic Fibrosis Organization.